Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 12 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 9567566

    HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted

  2. US 9562039

    Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities

    Almirall, S.A. · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted

  3. US 9556133

    Polycyclic LPA1 antagonist and uses thereof

    AMIRA PHARMACEUTICALS, INC. · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted

  4. US 9550742

    11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 24, 2017 · Expires Jan 19, 2037

    granted

  5. US 9549934

    Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

    Almirall, S.A. · Granted Jan 24, 2017 · Expires Jan 19, 2037

    granted

  6. US 9550818

    Methods for use of vascular endothelial growth factor antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 24, 2017 · Expires Jan 19, 2037

    granted

  7. US 9518091

    A4B7 peptide monomer and dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Dec 13, 2016 · Expires Dec 8, 2036

    granted

  8. US 9517228

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Dec 13, 2016 · Expires Dec 8, 2036

    granted

  9. US 9518050

    Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity

    Almirall, S.A. · Granted Dec 13, 2016 · Expires Dec 8, 2036

    granted

  10. US 9511140

    Stable VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 6, 2016 · Expires Dec 1, 2036

    granted

  11. US 9493564

    CD86 antagonist multi-target binding proteins

    Aptevo Research and Development LLC · Granted Nov 15, 2016 · Expires Nov 10, 2036

    granted

  12. US 9493467

    PI3 kinase antagonists

    The Regents of the University of California · Granted Nov 15, 2016 · Expires Nov 10, 2036

    granted

  13. US 9468624

    Small molecule antagonists of bacterial quorum-sensing receptors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted

  14. US 9452161

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted

  15. US 9441041

    Use of antagonists of the interaction between HIV GP120 and α4β7 integrin

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 13, 2016 · Expires Sep 8, 2036

    granted

  16. US 9428467

    Selective calcium channel antagonists

    Northwestern University · Granted Aug 30, 2016 · Expires Aug 25, 2036

    granted

  17. US 9422310

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Aug 23, 2016 · Expires Aug 18, 2036

    granted

  18. US 9416167

    Stable liquid formulations of dimer VEGF antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 16, 2016 · Expires Aug 11, 2036

    granted

  19. US 9394275

    Diamide compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity

    Theravance Respiratory Company, LLC · Granted Jul 19, 2016 · Expires Jul 14, 2036

    granted

  20. US 9365540

    Benzimidazole derivatives as MCH receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Jun 14, 2016 · Expires Jun 9, 2036

    granted

  21. US 9353108

    Tetrahydronaphthyridine somatostatin receptor 5 antagonists

    Takeda Pharmaceutical Company Limited · Granted May 31, 2016 · Expires May 26, 2036

    granted

  22. US 9353175

    Use of antagonists targeting metallothionein to treat intestinal inflammation

    UNIVERSITY OF CONNECTICUT · Granted May 31, 2016 · Expires May 26, 2036

    granted

  23. US 9346829

    5-HT3 receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted May 24, 2016 · Expires May 19, 2036

    granted

  24. US 9340594

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted May 17, 2016 · Expires May 12, 2036

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.